in 2022 NCCN Guidelines
The 2022 NCCN guidelines specifically recommend Decipher Prostate RP after radical prostatectomy and that men with high-risk scores (>0.6) should be strongly considered for salvage radiotherapy with the addition of concurrent hormone therapy, when early radiation therapy is missed.
The new NCCN recommendation is based on results of the NRG Oncology Phase 3 randomized controlled trial, RTOG 96-01. This study, which followed patients for a median of 12 years, demonstrated that:
In the subset of patients who received hormone therapy in addition to early salvage radiotherapy:
Decipher calculates a patient’s genomic risk without factoring in other clinical characteristics. This new and meaningful perspective provides greater clarity and confidence in determining the best treatment plan.